Forty four consecutive subjects aged 29-58 years (21 males and 23 females) with a clinical diagnosis of heterozygous familial hypercholesterolemia periodically treated every 30 days with LDL-apheresis for statin resistance, were enrolled in this study. A lipid profile was obtained immediately before starting LDL-apheresis, a second profile was obtained within four hours after LDL-apheresis. Chit activity and anti ox-LDL levels were determined with appropriate methods in all patients before and after LDL-apheresis.
Introduction Familial hypercholesterolemia (FH) is a genetic alteration of lipoprotein metabolism caused by defects in the low density lipoprotein receptor (LDLR)
. High LDL levels, secondary to the LDLR homozygous defect, are associated to significant increase of oxidized LDL (ox-LDL), which removed from circulation lead to massive lipid accumulation, foam cell formation in endothelial wall, often tendom xanthomas (TX) and corneal arcus (2) . Also the heterozygous FH (heFH), shows precocious coronary heart disease before 65 years old, if they are not treated (3) 
. Then FH represent a paradigmatic example of atherosclerosis produced by ox-LDL accumulation and a model to study the role of macrophage activation in atherosclerosis process (1). Generated ox-LDL induces an immune response with production of anti ox-LDL antibodies and macrophage cells could remove from circulation immune complexes anti ox-LDL/ ox-LDL through the Fc receptor for antibodies (4). Shoji et al, 2000 (5) found a inverse correlation among anti ox LDL and ox-LDL
in healthy individuals supporting the hypothesis that this mechanism is also operating in condition where ox LDL are stably low. This mechanism could be not sufficient to protect from foam cells generation in presence of a defect in LDLR gene, when the levels of ox-LDL are very high (6) .
Chitotriosidase (Chit) is one of the most quantitatively represented marker of macrophage activation, such as occurs in Gaucher disease, sarcoidosis, nonalcoholic liver disease and atherosclerosis (7-8-9). Plasma Chit activity has been associated with both the extension and prognosis of atherosclerotic vascular lesions in humans (10-11-12) and its phagocyte-specific expression supports a relevant role in innate immunity (13) .
Considering the importance of anti ox-LDL in the pathogenesis of atherosclerosis lesions (14) and the involvement of Chit activity in the evolution of atherosclerotic vascular lesions (10-11), we hypothesize a relation among these two factors. The objective of this study is to establish the relationship between lipid parameters, Chit activity and anti ox-LDL levels in a group of subjects with clinically and genetically defined heFH (total cholesterol consistently more than 400 mg/dl) before and after LDL-apheresis treatment. LDL-apheresis represents an effective therapy in heFH patients, who had no response to highest doses of statin drugs, and could restore the physiological mechanism of anti ox-LDL/ ox-LDL immunocomplexes clearance altered by LDLR genetic defect (15).
Material and methods

Study subjects
Consecutive 44 subjects aged 29-58 years (21 males and 23 females) with a clinical diagnosis of heFH were treated periodically with LDL-apheresis. The diagnosis of heFH was determined genetically in all patients (2) . They started LDL-apheresis treatment because their previous lipid lowering therapy (statin and benzafibrate) did not reduce the total and LDL cholesterol. A combination of discontinuous blood centrifugation (MCS 3p Haemonetics Corp., Braintree, MA, USA) and 2 steps membrane differential filtration were performed at interval of 30 days. Clinical data, history of prior cardiovascular disease (CVD) at early onset, demographic and anthropometric measurements, and an accurate physical examination in search of tendon xanthomas (TX) were obtained from each subject. Informed consent was obtained from all subjects and the ethical committee from each institution involved in this study approved the study.
Lipid Concentrations
To obtain a baseline lipid profile, overnight fasting blood was drawn immediately before starting LDL-apheresis. A second profile was obtained within four hours after LDL-apheresis. Total cholesterol and triglyceride levels were measured with standardized enzymatic methods. HDL cholesterol was measured by precipitation methods and LDL cholesterol was estimated with the Friedewald's formula, since no patient had triglycerides over 300 mg/dl. Lipoprotein (a) was determined in immunonephelometry with specific antibodies (New Scientific Company S.r.L., Cormano (MI), Italy).
Chitotriosidase Enzyme Assay
Chitotriosidase enzyme assay was based on the method described by Hollak et al. 1994 (7) , with minor modifications. Briefly, chitotriosidase activity was determined by 2) for 15 minutes at 37°C. The reaction was stopped by using 2 ml of 0.5 mol/L Na2CO3-NaHCO3 buffer, pH 10.7. The substrate hydrolysis by Chit produces the fluorescent molecule 4-methylumbelliferone, which was quantified with a Hitachi 2500 fluorometer, excitation at 366 nm and emission at 446 nm, and compared with a standard 4-methylumbelliferone calibration curve. Chit activity was expressed as nanomoles of substrate hydrolyzed per hour per milliliter of reaction mixture. Plasma Chit activity was measured by duplication and three QC samples from healthy adults were added in every set of determinations. The coefficient of variation was less than 5% in all cases.
Oxidized low-density lipoprotein antibodies
An enzyme-linked immunosorbent assay (ELISA) for the detection and quantification of IgG antibodies to oxidized low-density lipoprotein (ox-LDL) in human plasma was used (ImmuLisa™, IMMCO Diagnostics, Buffalo, NY, USA). The intensity of the color changes, proportionally to the antibodies concentration, was read as absorbance at 405 nm. Three QC samples from healthy adults were also added in each plate containing a calibration curve. The absorbance values on native LDL were subtracted from the absorbance obtained on ox-LDL for control, calibrators and specimens. The concentration of anti ox-LDL was determined from the calibration curve and the results are expressed in Enzyme Units per milliliter (EU/ml). Apolipoprotein E genotyping DNA from patients isolated by peripheral blood cells was used in a polymerase chain reaction (PCR) and Apolipoprotein E genotypes were determined by HhaI digestion as the methods decribed by Hixon and Vernier (16) , modified by Tsukamoto et al (17) .
LDLR genetic analyses
For LDLR gene analysis the entire gene was sequenced. Mutations in the LDLR gene causing FH were classified when possible, as receptor-defective or receptornegative on the basis of the residual LDLR activity. Mutation leading to a frame-shift and/or a truncated receptor were considered as receptor-negative (2, 6) .
Chitotriosidase polymorphism DNA from patients were used as template in subsequent PCR reactions. The duplication mutation analysis was performed using specific primers [Chs9 (AGCTATCTGAAGCAGAAG) and Chas8 (GGAGAAGCCGGCAAAGTC)] and two fragments of 75 and 99 base pairs were amplified from the wild and mutant CHIT gene, respectively. Electrophoresis in Metaphore gel (4%), allowed the detection of both fragments.
Statistical methods
The data are expressed as mean values with standard deviation (SD) for variables with normal distribution and as medians and range for variables with a skewed distribution. Statistical differences were computed by using the Student's t test or the Mann-Whitney U-test, respectively. Correlation and statistical analyses were performed with SSPS software (version 13.0), with significance set at P<0.05.
Results
In Table I , we show the clinical and biochemical characteristics of the 44 heFH subjects, including also the LDLR and CHIT genotype polymorphisms. No significant difference, among men and women, regarding age, body mass index, blood pressure was found and neither presence of hypertension nor diabetes. Differences were found in smoking habit, premature CVD, and age of first CVD event, being more smoker among the men group, who had more premature CVD, with minor age at the first event. Mean values of total cholesterol, LDL-cholesterol, triglycerides in the last few months were elevated in all subjects with no significant difference between men and women.
Table I. Clinical and laboratory characteristics of 44 heterozygous FH patients (21 men and 23 women).
Only men had significantly lower HDL cholesterol levels compared to women. No Chit deficient patients was found at the genotype analysis, 27 (61.4 %) were wild/wild and 17 (38.6%) wild/mut. Chit activity was found elevated before LDL-apheresis, without difference between males (11.94+8.68 nmol/ml/h) and females (12.26+7.70 nmol/ml/h), considering that 7.3±1.9 nmol/ml/h activity was found in healthy control of the same age in our laboratory. Also the anti ox-LDL were found elevated before LDL-apheresis in males (38.20+17.64 UI) and in females (55.80+38.97), considering that < 20 UI/ml was found in healthy control of the same age in our laboratory. The difference between males and females was not significant (P = 0.0646). In Table II are reported the levels of total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, Chit and anti ox-LDL before and after LDL-apheresis, considering separately males and females. All lipid parameters significantly decreased after LDL-apheresis (P < 0.0001). The reduction of Chit activity after LDL-apheresis was not significant as well as the reduction of anti ox-LDL concentration. Before and after LDL-apheresis the correlation between Chit and total cholesterol was negative (r = -0.44 and -0.50 respectively) and the same between Chit and LDL-cholesterol (r = -0.45 and -0.55 respectively) (Figure 1 a, b, c, d) . The correlation between HDL-cholesterol and Chit before and after LDL-apheresis was not significant. The anti ox-LDL concentration positively correlated with Chit activity (r = 0.52) and negatively with LDL-cholesterol (r = -0.32) and total cholesterol (r = -0.33) before LDL-apheresis (Figure 2 a, c, e ). After LDL-apheresis the correlation with Chit was maintained high (r = 0.63) and the correlation with LDL-cholesterol and total cholesterol remained significant (r = -0.21 and r = -0.35 respectively) (see Figure 2 b, d, f). Click figure However negative correlations were not maintained for high levels of total cholesterol and LDL-cholesterol, before LDL-apheresis. This was supported by the order-2 polynomial trend behavior showed in Figure 1 a and b, Figure 2 c and e. On the contrary, these trends were maintained, when the level of total cholesterol and LDL-cholesterol decreased after LDL-apheresis. 
Discussion
Plasma filtration represent an effective therapy in heFH patients, who had no response to highest doses of statin and could restore through a macrophage activation the physiological mechanism of remotion of anti ox-LDL/ ox-LDL immunocomplexes altered by LDLR genetic defect (15) .
In fact in this study we demonstrated a negative correlation among Chit activity, total and LDL-cholesterol before and after LDL-apheresis, which seems to be dependent by active macrophage removal of anti ox-LDL/ ox-LDL immunocomplexes. By removing LDL with LDL-apheresis, the anti-oxLDL/oxLDL ratio could increase and the excess of anti ox-LDL could induce macrophage activation through the surface Fc receptors. Alternatively with high levels of LDL-cholesterol, the deposition of foam cells represent the natural evolution of atherosclerosis process (as highlighted by the trend inversion above mentioned).
Hulthe et al 1998 (18) found, in a post hoc analysis, lower antibody titers in patients with a history of myocardial infarction, suggesting that antibodies against oxLDL could have a protective effect. This observation is in agreement with Tinahones et al 2002 (19) , who reported in literature a negative correlation among anti-oxLDL and total cholesterol in a population of 400 subjects from Malaga (Spain), suggesting again the active role of macrophage cells in the remotion of ox-LDL. The same authors (20) in a larger population (1354 subjects) found a very significant increase (P < 0.0001) of anti-ox-LDL: younger persons (16-35 years) had higher levels of anti ox-LDL (MDA-LDL) antibodies than persons older than 35 years (P = 0.05) and immune complexes were significantly higher (P = 0.05) in persons aged 5-15 years than in persons older than 40 years. On the contrary Artieda et al 2003 (10) reported an increased plasma Chit activity, independent from the distinct allelic or genotype distribution, in Spanish patients with atherothrombotic stroke and correlated plasma Chit activity to the severity of the atherosclerotic lesion (11) . Moreover, in Spanish hypercholesterolemic patients Canudas et al (21) found that no correlation exist between plasma Chit activity and the variation of plasma lipid levels before and after treatment with atorvastatin or bezafibrate. In our study plasma Chit activity, total and LDL-cholesterol levels correlated negatively before and after LDL-apheresis. These contrasting results could be due to different mechanism depending from the high level of ox-LDL in plasma, which could inhibit the re-modeling of vessel wall in defect of anti ox-LDL.
In fact the activation of macrophages within the atherosclerotic lesion could represent an attempt for re-modeling the vessel wall, which may control the growth of lipid plaques. In condition where the total cholesterol and LDL-cholesterol levels are maintained elevated, the negative trend which seems to demonstrate an active mechanism of immunocomplexes removal disappears, supporting the foam cells formation and subsequent deposition. Some years ago we demonstrated "in vitro" that the activation of macrophages was induced by formation of immunocomplexes anti ox-LDL/ ox-LDL through the Fc fragment receptor on the macrophage cell surface (22) . Recently this hypothesis was resumed by Fostergard et al 2007 (23) who demonstrated the importance of antibodies response, comparing two populations with different cardiovascular disease prevalence from New Guinea and from Sweeden. The discriminant factor among this two groups was a significant level of anti-phosphorylcholine antibodies of IgM subclass, which are active in the remotion of ox-LDL. Also in atherosclerosis mice model, the induced increase of anti ox-LDL appears to be protective, in fact several investigators have demonstrated with ox-LDL immunization (24) (25) or with S. Pneumonieae immunization (26) , that in such model the atherosclerosis development attenuates. This was also confirmed by an "in vivo" study which showed in Watanabe heritable hyper-lipidemic rabbits, lacking the LDL receptor and mimicking the human familial hypercholesterolemia. In this mice model the continuous auto-immunization with malondialdehyde-modified LDL, miming ox-LDL, results in a very high concentration of antibodies against ox-LDL, leading to significantly reduced progression of atherosclerosis (27) . This experiment opens the way to a model for the ox-LDL vaccination, with the aim to activate the macrophage system to clean the atheromatosis lesions. Moreover it is evident that the mechanism of active cleaning of atheromatosis lesions is working when the level of total cholesterol and LDL-cholesterol is kept sufficiently low (5).
This evidence was also supported by our computational model that was able to reproduce experimental data and is actually used for making predictions and evaluate biological hypothesis (28) .
In fact, LDL-apheresis is, up to date, the more active system for lowering LDL level in FH, and we found a negative correlation between anti ox-LDL, total cholesterol and LDL-cholesterol before and after LDL-apheresis, even plasma Chit activity and total and LDL-cholesterol correlated negatively before and after treatment. This stable response is explained by active remotion of immunocomplexes in these patients in the interval between LDL-apheresis. The increase of Chit activity was not found after statin treatment, probably because the modification of total cholesterol and LDL was not rapid enough to induce an activation of macrophage cells (21) . On the contrary Orem et al 2002 (29) reported after lipid lowering therapy with atorvastatin (10 mg/day) a significant decrement of anti ox-LDL and an increase of anti oxidant capacity of plasma LDL, which suggested again an active removal of immune complexes. They suggest also that the measurement of antibodies against ox-LDL during lipid-lowering therapy may be used as an important marker for monitoring in-vivo LDL oxidation and atherosclerotic processes.
In individuals where the LDL were reduced by LDL-apheresis or by statine treatment, an active mechanism may be operative clearing the surface of vessel as was reported in our beta-thalassemia patients (30) and in diabetes patients in statine treatment (22) protecting from ox-LDL vascular alteration.
